<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">human</item><item key="factors"><item><item key="GSE14842GSM371301"/></item><item><item key="GSE14842GSM371302"/></item><item><item key="GSE14842GSM371303"/></item><item><item key="GSE14842GSM371304"/></item><item><item key="GSE14842GSM371305"/></item><item><item key="GSE14842GSM371310"/></item><item><item key="GSE14842GSM371311"/></item><item><item key="GSE14842GSM371312"/></item><item><item key="GSE14842GSM371313"/></item><item><item key="GSE14842GSM371314"/></item><item><item key="GSE14842GSM371315"/></item><item><item key="GSE14842GSM371316"/></item><item><item key="GSE14842GSM371317"/></item><item><item key="GSE14842GSM371318"/></item></item><item key="id">3169</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">Increased numbers of mast cells and their products have been linked to symptom onset and severity in patients with chronic diarrhea and...</item><item key="geo_gse_id">E-GEOD-14842</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">0</item><item key="sample_count">14</item><item key="tags"><item>cell</item><item>diarrhea</item><item>genome</item><item>irritable bowel syndrome</item><item>syndrome</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_id_plat">E-GEOD-14842_A-AFFY-44</item><item key="slug">transcription-profiling-of-human-ibs-patients-befo</item><item key="geo_gds_id"/><item key="name">Transcription profiling of human IBS patients before and after treatment</item><item key="created">Sep.12, 2014</item><item key="summary">Increased numbers of mast cells and their products have been linked to symptom onset and severity in patients with chronic diarrhea and abdominal pain.  Although mast-cell inhibition ameliorates clinical manifestations and reduces mucosal inflammation, underlying molecular mechanisms remain unknown. Experiment Overall Design: Diarrhea-irritable bowel syndrome (d-IBS) patients were studied at baseline, or 6 months after natural evolution (control) or oral cromoglycate treatment. Jejunal biopsies were subjected to chip analysis (Affymetrix Human Genome U133 Plus 2.0 GeneChips).</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-14842</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-14842/samples/</item></data></biogps>
